Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Liposarcoma
- Angiosarcoma
- Epithelioid Sarcoma
- Fibrosarcoma
- Leiomyosarcoma
- Malignant Peripheral Nerve Sheath Tumor
- Myxofibrosarcoma
- Sarcoma, Soft Tissue
- Soft Tissue Sarcoma
- Synovial Sarcoma
- Undifferentiated Pleomorphic Sarcoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02584309
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Brian A Van Tine, M.D., Ph.D. Washington University School of Medicine